nach oben

Erschienen in:

08.04.2016 | Interventional

Robust evidence for long-term survival with ⁹⁰Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer

verfasst von: T. F. Jakobs, K. J. Paprottka, F. Raeßler, F. Strobl, S. Lehner, H. Ilhan, C. G. Trumm, W. P. Fendler, W. Sommer, P. M. Paprottka

Erschienen in: European Radiology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Our aim was to provide further evidence for the efficacy/safety of radioembolization using yttrium-90-resin microspheres for unresectable chemorefractory liver metastases from colorectal cancer (mCRC).

Methods

We followed 104 consecutively treated patients until death. Overall survival (OS) was calculated from the day of the first radioembolization procedure. Response was defined by changes in tumour volume as defined by Response Evaluation Criteria in Solid Tumours (RECIST) v1.0 and/or a ≥30 % reduction in serum carcinoembryonic antigen (CEA) at 3 months.

Results

Survival varied between 23 months in patients who had a complete response to prior chemotherapy and 13 months in patients with a partial response or stable disease. Median OS also significantly improved (from 5.8 months to 17.1 months) if response durability to radioembolization extended beyond 6 months. Patients with a positive trend in CEA serum levels (≥30 % reduction) at 3 months post-radioembolization also had a survival advantage compared with those who did not: 15.0 vs 6.7 months. Radioembolization was well tolerated. Grade 3 increases in bilirubin were reported in 5.0 % of patients at 3 months postprocedure.

Conclusions

After multiple chemotherapies, many patients still have a good performance status and are eligible for radioembolization. This single procedure can achieve meaningful survivals and is generally well tolerated.

Key Points

• After multiple chemotherapies, many patients are still eligible for radioembolization (RE).

• RE can achieve meaningful survival in patients with chemorefractory liver-predominant metastatic colorectal cancer (mCRC).

• Tumour responsiveness to prior systemic treatments is a significant determinant of overall survival (OS) after RE.

• Radioembolization in patients with a good performance status is generally well tolerated.

IARC IAfRoC (2014) GLOBOCAN: estimated incidence, mortality and prevalence worldwide in 2012 (population fact sheet in more developed countries). Copyright: IARC, Lyon, France. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Last accessed January 2014

Cartwright TH (2012) Treatment decisions after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 11:155–166CrossRefPubMed

Elferink MA, de Jong KP, Klaase JM, Siemerink EJ, de Wilt JH (2015) Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands. Int J Color Dis 30:205–212CrossRef

Ribero D, Vigano L, Amisano M, Capussotti L (2013) Prognostic factors after resection of colorectal liver metastases: from morphology to biology. Future Oncol 9:45–57CrossRefPubMed

Clark ME, Smith RR (2014) Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol 5:374–387PubMedPubMedCentral

Mi K, Kalady MF, Quintini C, Khorana AA (2015) Integrating systemic and surgical approaches to treating metastatic colorectal cancer. Surg Oncol Clin N Am 24:199–214CrossRefPubMed

Fiorentini G, Aliberti C, Mulazzani L et al (2014) Chemoembolization in colorectal liver metastases: the rebirth. Anticancer Res 34:575–584PubMed

Liu DM, Thakor A, Baerlocher M et al (2015) A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. Future Oncology (London, England). doi:10.2217/fon.15.3:1-8 PubMedCentral

Fiorentini G, Aliberti C, Tilli M et al (2012) Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32:1387–1395PubMed

10.

de Baere T, Tselikas L, Pearson E et al (2015) Interventional oncology for liver and lung metastases from colorectal cancer: the current state of the art. Diagn Interv Imaging. doi:10.1016/j.diii.2015.04.004

11.

Hendlisz A, Van den Eynde M, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694CrossRefPubMed

12.

Van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78–85CrossRefPubMed

13.

Kennedy AS (2014) Radiation oncology approaches in liver malignancies. Am Soc Clin Oncol Educ Book e150–e155. doi:10.14694/EdBook_AM.2014.34.e150

14.

Van Cutsem E, Cervantes A, Nordlinger B, Arnold D (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii1–iii9CrossRefPubMed

15.

Ahmadzadehfar H, Biersack HJ, Ezziddin S (2010) Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 40:105–121CrossRefPubMed

16.

Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF, Helmberger TK (2007) Developments and perspectives in radioablative techniques. Radiologe 47:1083–1088CrossRefPubMed

17.

Institute NC (2006) Common terminology criteria for adverse events v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

18.

Chalian H, Tore HG, Horowitz JM, Salem R, Miller FH, Yaghmai V (2011) Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics 31:2093–2105CrossRefPubMed

19.

Kennedy AS, Coldwell D, Nutting C et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65:412–425CrossRefPubMed

20.

Kennedy A, Ball D, Cohen Sea (2013) Safety and efficacy of resin 90Y-microspheres in 548 patients with colorectal liver metastases progressing on systemic chemotherapy. ASCO Gastrointestinal Cancers Symposium:Abs. 264

21.

Cosimelli M, Golfieri R, Pennington B, Sennfält K (2013) Selective internal radiotherapy (SIRT) using resin yttrium-90 resin microspheres for chemotherapy-refractory metastatic colorectal cancer: an Italian cost-effectiveness analysis. Value Health 16:A409CrossRef

22.

Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L (2015) Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol 22:794–802CrossRefPubMed

23.

Chapiro J, Duran R, Lin M et al (2015) Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumor response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol 25:1993–2003CrossRefPubMedPubMedCentral

24.

Hipps D, Ausania F, Manas DM, Rose JD, French JJ (2013) Selective Interarterial Radiation Therapy (SIRT) in colorectal liver metastases: how do we monitor response? HPB Surg 2013:570808CrossRefPubMedPubMedCentral

25.

Fendler WP, Ilhan H, Paprottka PM et al (2015) Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. Eur Radiol 25:2693–2700CrossRefPubMed

26.

Dixon MR, Haukoos JS, Udani SM et al (2003) Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg 138:962–966CrossRefPubMed

27.

Graf W, Bergstrom R, Pahlman L, Glimelius B (1994) Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 30a:453–457CrossRefPubMed

28.

Maisano R, Azzarello D, Del Medico P et al (2011) Alkaline phosphatase levels as a prognostic factor in metastatic colorectal cancer treated with the FOLFOX 4 regimen: a monoinstitutional retrospective study. Tumori 97:39–42PubMed

29.

Kennedy AS, Ball D, Cohen SJ et al (2015) Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncol 6:134–142PubMedPubMedCentral

30.

Aliberti C, Fiorentini G, Muzzio PC et al (2011) Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead(R), drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 31:4581–4587PubMed

31.

Martin RC, Joshi J, Robbins K et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18:192–198CrossRefPubMed

32.

Stutz M, Mamo A, Valenti D et al (2015) Real-life report on chemoembolization using DEBIRI for liver metastases from colorectal cancer. Gastroenterol Res Pract 2015:715102CrossRefPubMedPubMedCentral

Titel: Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer
verfasst von: T. F. Jakobs
K. J. Paprottka
F. Raeßler
F. Strobl
S. Lehner
H. Ilhan
C. G. Trumm
W. P. Fendler
W. Sommer
P. M. Paprottka
Publikationsdatum: 08.04.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 1/2017
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-016-4345-z

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Robust evidence for long-term survival with ⁹⁰Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

In vivo effects of bupivacaine and gadobutrol on the intervertebral disc following discoblock and discography: a histological analysis

Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort

Late recanalisation beyond 24 hours is associated with worse outcome: an observational study

Incidence and management of oesophageal ruptures following fluoroscopic balloon dilatation in children with benign strictures

Complication rates of CT-guided transthoracic lung biopsy: meta-analysis

Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie